Overview

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting

Trial end date:
2027-04-16

Target enrollment:

Participant gender:

Summary

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Shionogi Inc.

Treatments:

Pembrolizumab